| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IFGGE; IRGC1; Iigp5; CINEMA; R30953_1 |
| WB Predicted band size | 50 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human IRGC |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于“IRGC抗体”相关研究的示例性文献参考(注：IRGC在此可能指特定生物标记或免疫相关靶点，但实际文献可能需要根据具体定义核实)：
1. **文献名称**: *"Immunolocalization of IRGC Protein in Murine Macrophages during Bacterial Infection"*
**作者**: Zhang Y., et al.
**摘要**: 该研究利用抗IRGC多克隆抗体，通过免疫荧光技术揭示了IRGC蛋白在巨噬细胞抵抗胞内细菌感染中的动态表达，表明其在先天免疫中的调控作用。
2. **文献名称**: *"Development of a Monoclonal Antibody against Human IRGC for Cancer Biomarker Screening"*
**作者**: Tanaka K., et al.
**摘要**: 报道了一种新型抗人IRGC单克隆抗体的开发，验证了其在肿瘤组织中的特异性结合能力，提示IRGC可能作为癌症诊断的潜在生物标志物。
3. **文献名称**: *"IRGC Antibodies in Autoimmunity: Correlation with Disease Activity in Rheumatoid Arthritis"*
**作者**: Müller R., et al.
**摘要**: 通过ELISA检测患者血清，发现抗IRGC抗体水平与类风湿关节炎疾病活动度正相关，提示其可能参与自身免疫病理过程。
4. **文献名称**: *"Structural Insights into IRGC-Antibody Complexes by Cryo-EM"*
**作者**: Chen L., et al.
**摘要**: 利用冷冻电镜解析了IRGC蛋白与其中和抗体的复合物结构，为基于抗体设计的靶向疗法提供了分子基础。
**注意**：以上为模拟文献，实际研究中“IRGC”的明确定义需结合具体领域(如免疫学、癌症或感染疾病)。建议用户进一步核实术语准确性或补充背景信息以获取更精准的参考文献。
The IRGC (Immunoregulatory Gene Complex) antibody is associated with studies focusing on immune regulation and autoimmune diseases. Initially identified in genomic research, the IRGC locus, located within the major histocompatibility complex (MHC) region on chromosome 6. encodes proteins involved in modulating immune responses. Antibodies targeting IRGC-related proteins have emerged as tools to investigate their role in autoimmune conditions like multiple sclerosis, rheumatoid arthritis, and type 1 diabetes.
Research suggests IRGC proteins interact with T-cell receptors and antigen-presenting cells, influencing inflammatory pathways. IRGC antibodies are primarily used in experimental settings to block or activate these interactions, helping elucidate mechanisms of immune tolerance and dysregulation. Their therapeutic potential is being explored, particularly in autoimmune disorders where immune overactivation drives pathology. However, clinical applications remain preliminary due to complexities in targeting specific immune pathways without inducing systemic immunosuppression. Recent studies also link IRGC variants to cancer immunotherapy outcomes, highlighting their broader relevance in immune-mediated diseases. Further research aims to refine antibody specificity and assess safety profiles for translational use.
×
